D. Thaçi, “Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension”, J of Skin, vol. 6, no. 6, p. s68, Nov. 2022.